FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy

Joyce J. M., Degirmenci B., Jacobs S., McCook B., Avril N.

Clinical Nuclear Medicine, vol.30, no.8, pp.564-568, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 8
  • Publication Date: 2005
  • Doi Number: 10.1097/01.rlu.0000170086.45627.99
  • Journal Name: Clinical Nuclear Medicine
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.564-568
  • Keywords: Zevalin, yttrium-90 ibritumomab tiuxetan, radioimmunotherapy, PET CT, non-Hodgkin lymphoma
  • Dokuz Eylül University Affiliated: No

Abstract

Yttrium-90 ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals Corp., San Diego, CA) is the first radioimmunotherapy agent approved by the U.S. Food and Drug Administration (FDA) for treatment of non-Hodgkin lymphoma. In a randomized clinical trial comparing Zevalin with rituximab, the overall response rate was 80% and 56%, respectively. Response was determined by assessing the size of lymph nodes on CT scans. FDG PET has been well accepted as an accurate imaging study for staging non-Hodgkin lymphoma and evaluating response to treatment. Simultaneous FDG PET and CT imaging (PET CT) provides coregistered functional PET images with anatomic CT images. We describe 2 cases of non-Hodgkin lymphoma treated in which response was followed using PET CT. Copyright © 2005 by Lippincott Williams & Wilkins.